Skip to content
FDA Import Alert · 66-40

Veganic SKN Limited · Rocklea, AUSTRALIA

Listed 2026-01-08 · 15 product codes · Source: FDA Import Alert 66-40 · View on FDA

A facility listed under this company name on the FDA Import Alert list as checked on 2026-11-09. See the FDA page for the listed address and products. Full Import Alert list

Firm Record

Veganic SKN Limited

9 findings from 2 inspection documents published by regulators. Each row below says what its date means.

US FDA · 2026-07-28 ~ 2026-09-29

Areas cited

Material and supplier controlQuality unit oversightLaboratory and QC controlsStability and storageContamination controlDeviation, CAPA, and investigation

Published inspection documents

Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)). Your firm did not adequately test your incoming component, (b)(4) , for identity prior to use in manufacturing. (b)(4) is a component that is at high risk for (b)(4) contamination. Your firm also accepted the (b)(4) raw material based on the supplier’s certificate of analysis (COA), without establishing the reliability of each of your component suppliers’ analyses at appropriate intervals. Additionally, the (b)(4) lot you utilized for drug product production had expired. In your response, you state that you opened a CAPA, performed a risk assessment, and sent all remaining drums of (b)(4) out for testing. In addition, you state that your firm is evaluating the (b)(4) of your (b)(4) products to a lower-risk excipient, to eliminate supply chain risk in all future productions. Your response is inadequate. Your risk assessment is theoretical. You conclude that the risk is low based on (b)(4) and (b)(4) application. You did not correlate the assessment to the actual test results for all affected lots. Additionally, your firm acknowledges that identity testing based on supplier COA plus FTIR was inadequate for high-risk materials like (b)(4) , yet you still reference past acceptance decisions as part of your justification. Acknowledging the gap does not mitigate the fact that your product was released under a flawed system, without appropriate controls in place at the time. Further, while you describe retrospective testing of remaining drums, there is no clear discussion of drug product that had already been manufactured and potentially distributed using untested (b)(4) . There is no mention of an impact assessment or of any market action. While your response states that you will reformulate your finished drug products to remove (b)(4) , it lacks a retrospective assessment with supporting analytical testing for products containing materials at high risk for (b)(4) contamination that are still on the market and within expiry. Furthermore, your response did not include an assessment of your drug products to identify other components at risk for (b)(4) contamination and proposed corrective actions. Your response also lacks your interim plans, controls, or risk-mitigation strategies until you reformulate your finished drug products. Identity testing for (b)(4) and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for (b)(4) levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products. The use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high risk for (b)(4) contamination at (b)(4) In your response to this letter, provide: A commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4) . A full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4) ). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4) , including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter. A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation and periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4) , and certain additional high-risk components, we note that this includes the performance of parts A, B, and C of the USP monograph. The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine their acceptability for use in manufacturing. A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified, and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures. A summary of your program for qualifying and overseeing contract facilities that test the components you use to manufacture your drugs. A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program. 2026-09-29 US FDA 3 findingsMaterial and supplier control · Quality unit oversight and 1 more View the regulator's official source

Other companies with similar findings

Other companies with findings worded closely to this company's. Only documents of the same type are compared.

A record as of publication. Check the agency's own announcements for any later corrective action.

What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.

Full history of Veganic SKN Limited — including inspection classifications Browse by document Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.